Close Menu

BioFire

The firm expects organic revenue growth of approximately 11 percent at constant exchange rates compared to the second quarter last year.

A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.

The panel is designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens.

First quarter revenue growth was driven by "unprecedented demand" for molecular biology products for use in COVID-19 testing.

The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.

Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.

Labrador Diagnostics, a firm controlled by an investment group that acquired Theranos' IP, alleged BioFire's FilmArray products infringe two patents.

SARS-CoV-2 viral material is available for test validation, and the FDA is conducting a rolling review process with an abbreviated submission template.

In the quarter, the firm entered a partnership with Specific Diagnostics and also submitted an enhanced version of its blood culture ID panel for regulatory clearance.

Qiagen, which is also developing a single-plex qRT-PCR assay for SARS-CoV-2, said it will have a syndromic panel including targets for the virus ready this month.

Pages